@BarrelSitterI just had a better look and Biotome are using...

@BarrelSitter
I just had a better look and Biotome are using peptides so not VOCs

BIOTOME PTY LTD
About: Biotome develops antibody-tests for stomach cancer and SARS-CoV-2. We
create next-generation serology tests, using peptides instead of whole proteins as
markers to harnesses the inherently high resolution of the immune system. Our tests
will be based on state-of-the-art electrochemical biosensors, which allows for label-free
detection suitable for rapid point-of-care testing.
Value proposition: Our technology has the capacity to deliver point-of-care antibody
tests with the same accuracy as the best laboratory-based antibody-tests, lower-cost
of production than lateral-flow rapid tests, the same simple user-interface as a glucose test, while providing better qualitative information regarding neutralising antibodies and
immunity than any available antibody-test.
Significant milestones met: We have:
• a granted patent for next-generation serology markers of stomach cancer risk.
• identified markers for SARS-CoV-2 infection that can identify neutralising antibodies
and distinguish between mild and severe disease.
• partnered with a manufacturer of ultra-low-cost high-sensitivity biosensor chips
suitable for our peptide markers.